Pharming Group N.V annual total debt
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Total Debt Growth & History (PHAR)
Pharming Group N.V's total debt was $17.7M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.7M | −$12.2M | −40.77% |
| 2024 | 2024-12-31 | $29.9M | −$3.2M | −9.69% |
| 2023 | 2023-12-31 | $33.1M | −$185,000 | −0.56% |
| 2022 | 2022-12-31 | $33.3M | $12.4M | +59.56% |
| 2021 | 2021-12-31 | $20.9M | $10.7M | +104.82% |
| 2020 | 2020-12-31 | $10.2M | $3.1M | +44.06% |
| 2019 | 2019-12-31 | $7.1M | — | — |
Pharming Group N.V quarterly total debt
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $113.3M | −$15.0M | −11.71% |
| Q1 2026 | 2026-03-31 | $116.2M | — | — |
| Q4 2025 | 2025-12-31 | $17.7M | −$12.2M | −40.77% |
| Q3 2025 | 2025-09-30 | $130.9M | — | — |
| Q2 2025 | 2025-06-30 | $128.3M | — | — |
| Q4 2024 | 2024-12-31 | $29.9M | −$3.2M | −9.69% |
| Q4 2023 | 2023-12-31 | $33.1M | −$185,000 | −0.56% |
| Q4 2022 | 2022-12-31 | $33.3M | $12.4M | +59.56% |
| Q4 2021 | 2021-12-31 | $20.9M | $10.7M | +104.82% |
| Q4 2020 | 2020-12-31 | $10.2M | — | — |
Pharming Group N.V total debt trends
Over the last five fiscal years, Pharming Group N.V's total debt increased from $10.2M to $17.7M, a change of $7.5M. The latest reported quarter, Q2 2026, shows $113.3M.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...